http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Gul Maleeha (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
ZEB ALAM,Gul Maleeha,Nguyen Thi-Thao-Linh,맹한주 한국약제학회 2022 Journal of Pharmaceutical Investigation Vol.52 No.6
Background Controlled release and targeted delivery of the drug payload are the two most fascinating applications of nanoparticle-based systems explored in the recent past. The advantages of achieving control over drug release kinetics include prolonged therapeutic effects, reduced dosing frequency, and fewer plasma level fluctuations and side effects, whereas targeted delivery offers enhanced drug accumulation at the site of action and reduced off-target toxicity, thereby improving the management of chronic diseases. Poly(lactic-co-glycolic acid) nanoparticles (PLGA-NPs) hold tremendous promise for such applications because of their ability to modulate drug release, pharmacokinetics, the biodistribution profiles of drugs, and the surface functionalization for targeted delivery. Area covered This review primarily highlights the applications of PLGA-NPs based on the controlled release of therapeutics after oral, parenteral, pulmonary, ocular, intranasal, and dermal administration and tissue engineering. The potential of PLGA-NPs for targeted delivery to various diseases, such as cancer, rheumatoid arthritis, inflammatory bowel disease, and neurological disorders, has also been extensively reviewed. This review concludes with a description of the limitations of PLGA-NPs and the hurdles associated with their clinical application. Expert opinion PLGA-NPs stand out among other nanoparticles because of their excellent biocompatibility and biodegradability. Although the presented data suggest that they are the major shareholders in controlled-release and targeted-delivery systems, no PLGA-NP formulation has reached clinics. Therefore, further insights into the rational design of PLGA-NPs and clinically relevant testing are required to narrow the gap between the bench and bedside realities.
-
ZEB ALAM,Gul Maleeha,Nguyen Thi-Thao-Linh,맹한주 한국약제학회 2023 Journal of Pharmaceutical Investigation Vol.53 No.6
Background Cancer remains a major global health burden and existing therapeutic approaches face substantial challenges such as drug resistance, poor selectivity, heterogeneity, and the complex tumor microenvironment. Nanotechnology has evolved into a promising tool with huge potential for application in the field of medicine. Recently, inorganic nanoparticles (INPs) have been widely explored for cancer therapy because of their distinct tunable physicochemical properties, biocompatibility, and versatile preparation methods. In addition, surface functionalization of INPs has further improved therapeutics efficacy by modulating their features, such as poor aqueous solubility, in vivo stability, potential toxicity, enhanced cancer targeting, and reduced binding to healthy cells. Area covered In this review, we briefly highlight a few of the most commonly used INPs in cancer therapy, along with their basic features and fabrication methods. Strategies, commonly employed materials and reasons for surface functionalization of INPs have also been described. Furthermore, the latest drug delivery and therapeutic applications of surface-functionalized INPs in various cancers were extensively reviewed. This review concludes with a future outlook and a few limitations of surface-functionalized INPs that hinder their clinical application. Expert opinion The presented data undoubtedly prove the potential of surface-functionalized INPs to improve therapeutic efficacy, cellular uptake, and tumor growth inhibition of anti-tumor drugs, thereby minimizing their limitations in cancer therapy. However, functionalized INPs have a negligible presence in the market for cancer therapy despite their promising potential. Appropriate designing and clinically relevant testing may facilitate their clinical translation into safe and effective cancer therapy in the near future.
-
Bae Yumi,Zeb Alam,Choi Ho-Ik,류정수,Gul Maleeha,Noh Ha-Yeon,Cho Junho,Gil Junkyung,Shah Fawad Ali,Chang Sun-Young,Bae Ok-Nam,Kim Jin-Ki 한국약제학회 2024 Journal of Pharmaceutical Investigation Vol.54 No.5
Purpose Dexamethasone palmitate (DXPL) is a lipophilic derivative of dexamethasone (DXM) used to overcome the low drug-loading capacity and immediate release characteristics of DXM from nanoparticles. In this study, we investigated the potential of DXPL-loaded solid lipid nanoparticles (DXPL-SLNs) to increase drug encapsulation efficiency, prolong drug release, and alleviate skin inflammation. Methods DXPL-SLNs were prepared using the nano-emulsion template technique with trilaurin as a lipid matrix and Tween 20, Span 20, and Brij 58 as a surfactant mixture. The physicochemical properties of DXPL-SLNs were examined in terms of particle size, polydispersity index, zeta potential, encapsulation efficiency, loading capacity, morphology, and crystalline behavior. The in vitro release profile of DXM from the DXPL-SLNs incubated in mouse plasma was assessed using a plasma conversion assay. In vivo anti-inflammatory effects of topically applied DXPL-SLNs were evaluated in mice with 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced ear edema. Results The optimized DXPL-SLNs (DXPL/trilaurin/Tween 20/Span 20/Brij 58:4/2/2/0.2/4, w/w ratio, respectively) displayed a mean particle size of 182.8 ± 2.7 nm with a very high drug loading capacity of 30.4%. DXPL-SLNs showed substantially prolonged drug release in mouse plasma compared to DXPL solution. Furthermore, DXPL-SLNs showed enhanced anti-inflammatory effects by efficiently reducing TPA-induced ear edema. Conclusion These findings suggest that DXPL-SLNs have great potential as anti-inflammatory therapeutics against acute skin inflammation.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
